We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Oxytocinis a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Oxytocin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2000–2022 with a typical study size of 52 participants.
Based on 12 studies · 6 meta-analyses · 5 RCTs · 367 total participants
Confidence
HighBy outcome
Oxytocin has an evidence score of 4/10 — emerging evidence based on 12 indexed studies, including 6 meta-analyses. A nine-amino-acid hormone with two very different stories. As an IV drug (Pitocin/Syntocinon) it is an established, supervised hospital medicine for inducing/augmenting labor and controlling postpartum bleeding. As a grey-market intranasal 'love/bonding/trust' spray it is largely UNPROVEN — the largest, most rigorous autism RCT (Sikich 2021, NEJM) was negative on its primary outcome, and replication of the famous single-dose social effects has been poor. Representative study: PMID 24173606.
The commonly studied dose of Oxytocin is No legitimate consumer dose. Medical IV oxytocin is titrated by clinicians under monitoring; intranasal doses used in research trials are typically 18-48 IU/day, but this use is investigational and not endorsed for self-administration.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Casein Hydrolysate
Mostly mechanism / observationalA milk-derived bioactive peptide — a tryptic hydrolysate of bovine αs1-casein standardized to the decapeptide α-casozepine (Lactium) — marketed for stress, anxiety, and sleep. Honest appraisal: the mechanism is real and food-derived (α-casozepine binds the benzodiazepine site of the GABA-A receptor in vitro), and a handful of small human RCTs show modest reductions in stress symptoms and cortisol plus some sleep-diary improvements. But several trials are industry-linked, two well-designed sleep RCTs were null on their primary endpoint, and effects are small. Well-tolerated; this is an ordinary dietary supplement, not a drug.
Last reviewed June 2026 · evidence from 12 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Oxytocin
A nine-amino-acid hormone with two very different stories. As an IV drug (Pitocin/Syntocinon) it is an established, supervised hospital medicine for inducing/augmenting labor and controlling postpartum bleeding. As a grey-market intranasal 'love/bonding/trust' spray it is largely UNPROVEN — the largest, most rigorous autism RCT (Sikich 2021, NEJM) was negative on its primary outcome, and replication of the famous single-dose social effects has been poor.
The popular intranasal social use scores low because the largest RCT (Sikich 2021, NEJM, n=290) was null and meta-analyses are mixed-to-weak; only supervised IV obstetric use is well-established.
Oxytocin is a hypothalamic neuropeptide that acts both as a circulating hormone and as a central neuromodulator. The honest evidence picture splits sharply by use.
(1) Medical/obstetric use: intravenous oxytocin (Pitocin, Syntocinon) is a long-established, FDA-approved drug given under continuous monitoring to induce or augment labor and to prevent/treat postpartum haemorrhage via uterine contraction; it also drives the milk-ejection (let-down) reflex in lactation.
This use is real and supervised, but it is a hospital intervention with risks (uterine hyperstimulation, fetal heart-rate changes, rare uterine rupture, water intoxication/hyponatraemia from antidiuretic activity) — not something to self-administer.
(2) Intranasal behavioural/psychiatric use: after early single-dose studies suggested oxytocin nasal spray could increase trust (Kosfeld 2005, Nature) and social cognition, it was widely hyped as a 'love hormone' and marketed grey-market for bonding, social anxiety, and autism.
The rigorous follow-up has been largely disappointing. The landmark phase-2 NIH multisite RCT in 290 autistic children and adolescents (Sikich 2021, NEJM, 24 weeks) found NO significant benefit on its primary social-withdrawal outcome versus placebo.
Meta-analyses of repeated intranasal oxytocin in autism and schizophrenia are mixed-to-null: some report a small effect on isolated social-cognition sub-measures, but overall core-symptom benefit is weak, inconsistent, and not robust to publication bias and trial quality. Brain-imaging trust studies (e.g.
Baumgartner 2008) are mechanistically interesting but small. The overall evidence for the popular intranasal social/behavioural use is therefore emerging at best and substantially over-sold relative to the data.
Binds the oxytocin receptor (OXTR), a G-protein-coupled receptor. In the periphery this triggers uterine smooth-muscle contraction and mammary myoepithelial contraction (milk ejection); in the brain (amygdala, striatum, hypothalamus) it modulates social-salience and threat-processing circuits.
Intranasal oxytocin is proposed to dampen amygdala threat reactivity and bias attention toward social cues. fMRI work links it to reduced amygdala/midbrain activation during trust adaptation — but behavioural translation in patient RCTs has been weak.
The well-established peripheral action: dose-dependent uterine contraction (labor induction/augmentation, postpartum haemostasis) and triggering of the milk-ejection reflex during lactation.
How Oxytocin works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
No legitimate consumer dose. Medical IV oxytocin is titrated by clinicians under monitoring; intranasal doses used in research trials are typically 18-48 IU/day, but this use is investigational and not endorsed for self-administration.
Can be taken without food
| Form | Type |
|---|---|
| 💊Intravenous (prescription, hospital use) | Recommended |
| 💨Intranasal spray (investigational / grey-market) | Alternative |
The IV form is an approved obstetric drug. The intranasal form is the one sold for social/bonding claims and is the form with the disappointing behavioural evidence.
Minimum: 1 weeks
Optimal: 24 weeks
Cycling: Not required
Note: No validated consumer schedule. Research intranasal dosing is once-twice daily; medical IV use is clinician-titrated under monitoring.
Dose-response data unavailable. The current published research for Oxytocin does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
IV oxytocin reliably induces and augments labor and contracts the postpartum uterus — an established hospital use under monitoring, not a self-administered effect.
Single doses sometimes shift isolated lab measures (theory-of-mind, trust games), but effects are small, inconsistent, and often fail to replicate in well-powered trials.
The 290-participant Sikich 2021 NEJM phase-2 RCT found no significant benefit on social withdrawal over 24 weeks. Meta-analytic signals on sub-measures are weak.
Oxytocin has antidiuretic (vasopressin-like) activity; high-dose IV exposure with fluids can cause water intoxication and hyponatraemia. Mood/affect effects of intranasal use are reported but poorly characterised.
IV oxytocin is used IN labor under continuous medical supervision — never self-administer. Do not use intranasal/grey-market oxytocin in pregnancy.
The largest, most rigorous RCT was negative; do not expect benefit from grey-market intranasal oxytocin. Discuss any interest with a clinician.
Oxytocin can affect blood pressure and sodium balance — medical use requires monitoring.
Severe hypertension has been reported when oxytocin is given with vasopressors; relevant to the medical IV setting.
Combined uterotonic use can cause uterine hyperstimulation — managed by clinicians in the obstetric setting.
Tip: Clinician titration and continuous monitoring; reduce/stop infusion
Tip: Limit electrolyte-free fluids; monitor sodium
Tip: Reported with intranasal use; reduce/stop
Tip: Poorly characterised with intranasal use; discontinue if troublesome
Timing is flexible for Oxytocin — consistent daily use matters more than the time of day. Research trials administer intranasal oxytocin once or twice daily (e.g.
Oxytocin should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are uterine hyperstimulation / tachysystole (IV use), hyponatraemia / water intoxication (high-dose IV), headache / nausea. Use caution if any of these apply to you: Self-administration in pregnancy outside clinical supervision; Use of medical IV oxytocin except in a monitored hospital setting; Known hypersensitivity to oxytocin.
Cerebrolysin
Mostly mechanism / observationalAn injectable neuropeptide preparation made from enzymatically digested pig (porcine) brain tissue — a mix of low-molecular-weight peptides and free amino acids marketed as a neurotrophic agent for stroke, dementia and traumatic brain injury. It is approved and widely used in Russia, China and parts of Europe/Asia, but is NOT FDA-approved. Honest appraisal: the highest-quality syntheses contradict the marketing. The Cochrane review of acute ischaemic stroke found no benefit on death or function and a possible harm signal (more non-fatal serious adverse events); the Cochrane review of vascular dementia rated the evidence very-low-quality and warned any benefit may be too small to matter. Many positive trials and meta-analyses are industry-funded and heterogeneous.
Tap node to isolate • Pinch to zoom • Tap edge for research
Oxytocin's antidiuretic activity plus excess electrolyte-free fluid can cause water intoxication and hyponatraemia.